Eloxx reports ELX-02 Phase 2 topline: one patient remission; opens $50M ATM offering

Eloxx Pharmaceuticals, Inc.

One of two completed patients achieved remission (≥50% UPCR decline); five of eight readings averaged 53% below baseline.
Second patient showed no significant UPCR change; both had same Col4A4 mutation but different RAAS inhibitor levels.
ELX-02 generally well tolerated; no discontinuations; kidney biopsies showed no nephrotoxicity.
Entered ATM agreement with Oppenheimer for up to $50M common stock sales, currently limited to $6.5M due to S-3 limits.
Prior SVB Leerink ATM agreement terminated; no shares were sold under that agreement.

item 1.01 item 1.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Eloxx Pharmaceuticals, Inc. terminated SVB Sales Agreement with SVB Leerink LLC (effective 2023-05-24).

Action: termination
Agreement: atm program
Counterparty: SVB Leerink LLC
Effective: 2023-05-24

Exact text from the filing

nto a Sales Agreement (the “SVB Sales Agreement”) with SVB Leerink LLC (“Cowen”) to sell shares of the Company’s Common Stock with aggregate gross sales proceeds of up to $50 million, from time to time, through an “at the market” equity

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Eloxx Pharmaceuticals, Inc. entered into Oppenheimer Sales Agreement with Oppenheimer & Co. Inc. valued at aggregate gross sales proceeds of up to $50.0 million (effective 2023-05-24).

Action: entry
Agreement: atm program
Counterparty: Oppenheimer & Co. Inc.
Value: aggregate gross sales proceeds of up to $50.0 million
Effective: 2023-05-24

Exact text from the filing

On May 24, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Oppenheimer Sales Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”) pursuant to which the Company may offer and sell shares of its common stock, par value $0.01 per share (the “Common Stock”), having aggregate gross sales proceeds of up to $50.0 million

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-063884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.